50 completed, 6 unknown, 1 active not recruiting, 1 recruiting. 25 Phase 3, 15 Phase 2, 8 Phase 4, 4 Early Phase 1, 4 Phase 1.
Follow Glabellar Frown Lines: new trials by email Literature Review of Glabellar Frown Lines trials Research Report on Glabellar Frown Lines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides Botulinum toxin type A - Wrinkle, Glabellar Frown Lines | Phase 4 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 325 | 2026-02-02 | 2026-08-14 |
| Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids zinc citrate 50 mg, Placebo Microcrystalline Cellulose - Adjuvant Zinc May Increase the Efficacy of Botulinum Toxin, Zinc Supplementation for Botulinum Toxin Treatment of the Forehead | Not applicable | Withdrawn | University of New Mexico | 2024-08-01 | 2024-09-19 | |
| A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101) CU-20101 treatment for Moderate to Severe Glabellar Striae, BOTOX® - Glabellar Frown Lines | Phase 3 | Completed | Cutia Therapeutics（Wuxi）Co.,Ltd | 554 | 2024-06-24 | 2026-06-15 |
| A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines Abobotulinumtoxin A (Espad Pharmed Darou Co.), Abobotulinumtoxin A (Ipsen Co.) - Glabellar Lines, Glabellar Frown Lines | Phase 3 | Completed | Espad Pharmed | 146 | 2024-05-28 | 2025-05-07 |
| Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines DAXXIFY - Glabellar Frown Lines | Phase 2 | Completed | Revance Therapeutics, Inc. | 27 | 2024-04-08 | 2025-04-04 |
| The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines PROTOXIN - Glabellar Frown Lines | Phase 3 | Completed | Protox Inc. | 155 | 2023-12-18 | 2024-06-21 |
| Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines prabotulinumtoxinA - Glabellar Frown Lines | Completed | Evolus, Inc. | 756 | 2023-03-15 | 2026-06-30 | |
| Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines onabotulinumtoxinA at a depth of 2mm, onabotulinumtoxinA at a depth of 4mm - Glabellar Frown Lines | Phase 1 | Active not recruiting | Henry Ford Health System | 20 | 2023-03-14 | 2026-03-12 |
| The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines PROTOXIN, Botox® - Glabellar Frown Lines | Phase 3 | Completed | Protox Inc. | 269 | 2023-03-06 | 2023-11-18 |
| Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines QM1114-DP - Glabellar Frown Lines, Canthal Lines | Phase 3 | Completed | Galderma R&D | 25 | 2023-01-23 | 2026-05-29 |
| Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines ATGC-110, Xeomin® - Glabellar Frown Lines | Phase 3 | Unknown | ATGC Co., Ltd. | 300 | 2022-10-11 | 2023-02-03 |
| AI-09 In Subjects With Glabellar Lines, GL-101 AI-09, Vehicle - Glabellar Frown Lines | Phase 1 / Phase 2 | Completed | Eirion Therapeutics Inc. | 96 | 2022-10-03 | 2026-08-31 |
| Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines QM1114-DP, Placebo - Glabellar Frown Lines | Phase 3 | Completed | Galderma R&D | 132 | 2022-05-09 | 2024-10-21 |
| Xeomin Treatment of Glabellar Lines Using OLD Versus COLD IncobotulinumtoxinA - Glabellar Frown Lines | Early Phase 1 | Unknown | Clinical Testing of Beverly Hills | 40 | 2022-05-01 | 2022-03-31 |
| Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA - Glabellar Frown Lines | Phase 2 | Completed | Evolus, Inc. | 154 | 2022-03-30 | 2024-09-04 |
| Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines MBA-P01 - Glabellar Frown Lines | Phase 3 | Completed | Medytox Korea | 253 | 2022-02-07 | 2024-01-16 |
| Study Comparing Treatment With Alluzience vs Reconstituted Toxin Alluzience, powder BoNT-A (BOTOX/Vistabel) - Glabellar Frown Lines | Phase 4 | Completed | Galderma R&D | 150 | 2022-02-04 | 2024-02-16 |
| A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines MBA-P01 (Botulinum toxin A), Placebo - Glabellar Frown Lines | Phase 2 | Completed | Medytox Korea | 50 | 2021-12-28 | 2023-02-24 |
| Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD prabotulinumtoxinA - Glabellar Frown Lines | Early Phase 1 | Completed | Clinical Testing of Beverly Hills | 30 | 2021-12-16 | 2024-02-06 |
| Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines OnabotulinumtoxinA - Glabellar Frown Lines | Early Phase 1 | Unknown | Clinical Testing of Beverly Hills | 40 | 2021-10-20 | 2021-10-27 |
Showing 20 of 59. Sign in to see all of them.
Behavior (1) · Communication (1) · Nonverbal Communication (1)
Botulinum Toxins, Type A (36) · incobotulinumtoxinA (7) · abobotulinumtoxinA (5) · DWP450 (4) · prabotulinumtoxin A (4) · Injections (3) · Botulinum Toxins (2) · Saline Solution (2) · Sodium Chloride (2) · Therapeutics (2) · coretox (1) · onabotulinum toxin A (1)
Galderma R&D (9) · Evolus, Inc. (6) · Medy-Tox (6) · Revance Therapeutics, Inc. (5) · Clinical Testing of Beverly Hills (3) · Croma-Pharma GmbH (3) · Medytox Korea (3) · Merz Pharmaceuticals GmbH (3) · Protox Inc. (3) · ATGC Co., Ltd. (2) · Allergan (2) · Pacira Pharmaceuticals, Inc (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Cutia Therapeutics（Wuxi）Co.,Ltd (1) · Eirion Therapeutics Inc. (1)
United States (29) · South Korea (12) · Germany (7) · Canada (5) · Australia (2) · United Kingdom (2) · Austria (1) · China (1) · Egypt (1) · France (1) · Iran (1) · Netherlands (1) · Poland (1) · Russia (1) · Sweden (1)
Rui Avelar, MD (5) · John Joseph, MD (3) · Alireza Firooz, Medical Doctor (1) · Anna Rostedt Punga, MD (1) · Beomjoon Kim (1) · Beomjoon Kim, PI (1) · Daniel Mueller, Dr. (1) · David Ozog, MD (1) · Huh Changhun, M.D. (1) · Jan de Lange, MD DMD PhD (1) · Jeffrey Adelglass, Dr. (1)
PMID 38470985, PMID 31609882, PMID 31791824, PMID 21134045, PMID 22453589, PMID 26233808, PMID 26509943, PMID 28614091, PMID 32773446, PMID 32773447, PMID 33065952, PMID 33950373, PMID 38807515, PMID 39462517, PMID 41607140
2008 (1), 2015 (1)